PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：5
|
作者：
Dimopoulos, M. [1 ]
Sonneveld, P. [2 ]
Nahi, H. [3 ]
Kumar, S. [4 ]
Hashim, M. [5 ]
Kulakova, M. [5 ]
Duran, M. [5 ]
Heeg, B. [5 ]
Lam, A. [6 ]
Dearden, L. [6 ]
机构：
[1] Univ Athens, Athens, Greece
[2] Erasmus MC, Rotterdam, Netherlands
[3] Karolinska Inst, Stockholm, Sweden
[4] Mayo Clin, Rochester, MN USA
[5] Ingress Hlth, Rotterdam, Netherlands
[6] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.064
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CN5
引用
收藏
页码：A408 / A408
页数：1
相关论文
共 50 条
  • [1] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [2] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 147 - 148
  • [3] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [4] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [5] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [6] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [7] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    [J]. CANCER, 2014, 120 (01) : 52 - 60
  • [8] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    [J]. LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [9] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    [J]. Leukemia, 2011, 25 : 1620 - 1626
  • [10] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    [J]. BLOOD, 2023, 142
12345